van Dijk Christiansen P, Sikjaer T, Andreasen C, Thomsen J, Bruel A, Hauge E
JBMR Plus. 2023; 7(12):e10829.
PMID: 38130746
PMC: 10731115.
DOI: 10.1002/jbm4.10829.
Wang W, Azar T, Tseng W, Pei S, Zhou Y, Jiang X
J Bone Miner Res. 2022; 37(11):2215-2225.
PMID: 36093591
PMC: 9712255.
DOI: 10.1002/jbmr.4704.
Chavassieux P, Chapurlat R
Front Endocrinol (Lausanne). 2022; 13:907914.
PMID: 35966102
PMC: 9368205.
DOI: 10.3389/fendo.2022.907914.
Wang W, Tseng W, Zhao H, Azar T, Pei S, Jiang X
Biomaterials. 2021; 276:121015.
PMID: 34273687
PMC: 8523222.
DOI: 10.1016/j.biomaterials.2021.121015.
Altman-Singles A, Jeong Y, Tseng W, de Bakker C, Zhao H, Lott C
J Bone Miner Res. 2017; 32(8):1703-1715.
PMID: 28467646
PMC: 5550334.
DOI: 10.1002/jbmr.3165.
Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials.
Zhang Q, Qian J, Zhu Y
Int J Clin Exp Med. 2015; 8(3):3338-48.
PMID: 26064224
PMC: 4443058.
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz D, Bonnet N, Baldock P, Ominsky M, Stolina M, Kostenuik P
J Biol Chem. 2010; 285(36):28164-73.
PMID: 20558734
PMC: 2934681.
DOI: 10.1074/jbc.M110.101964.
The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.
Yoshida T, Clark M, Stern P
J Cell Biochem. 2009; 106(5):896-902.
PMID: 19184980
PMC: 2702993.
DOI: 10.1002/jcb.22059.
Endogenous FGF-2 is critically important in PTH anabolic effects on bone.
Sabbieti M, Agas D, Xiao L, Marchetti L, Coffin J, Doetschman T
J Cell Physiol. 2008; 219(1):143-51.
PMID: 19107841
PMC: 2763338.
DOI: 10.1002/jcp.21661.
Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T
J Bone Miner Metab. 2008; 26(6):624-34.
PMID: 18979163
DOI: 10.1007/s00774-008-0871-3.
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
Lindsay R, Miller P, Pohl G, Glass E, Chen P, Krege J
Osteoporos Int. 2008; 20(6):943-8.
PMID: 18923884
DOI: 10.1007/s00198-008-0766-0.
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.
Martin T, Sims N, Ng K
Osteoporos Int. 2008; 19(8):1125-38.
PMID: 18338097
DOI: 10.1007/s00198-008-0575-5.
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D
CMAJ. 2006; 175(1):52-9.
PMID: 16818910
PMC: 1482742.
DOI: 10.1503/cmaj.050929.
How to grow bone to treat osteoporosis and mend fractures.
Whitfield J
Curr Osteoporos Rep. 2005; 1(1):32-40.
PMID: 16036063
DOI: 10.1007/s11914-003-0006-7.
How to grow bone to treat osteoporosis and mend fractures.
Whitfield J
Curr Rheumatol Rep. 2003; 5(1):45-56.
PMID: 12590885
DOI: 10.1007/s11926-003-0083-8.
The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.
Whitfield J, Morley P, Willick G
Drugs Aging. 1999; 15(2):117-29.
PMID: 10495071
DOI: 10.2165/00002512-199915020-00005.
Stemming bone loss by suppressing apoptosis.
Hock J
J Clin Invest. 1999; 104(4):371-3.
PMID: 10449428
PMC: 408531.
DOI: 10.1172/JCI7991.
Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (Ostabolin).
Whitfield J, Morley P, Willick G, ROSS V, Barbier J, Isaacs R
Calcif Tissue Int. 1996; 58(2):81-7.
PMID: 8998682
DOI: 10.1007/BF02529728.
